Management of schizophrenia

Last updated
Management of schizophrenia
Specialty Psychiatry

The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity. [1]

Contents

Hospitalization

Hospitalization may occur with severe episodes of schizophrenia. This can be voluntary or (if mental health legislation allows it) involuntary (called civil or involuntary commitment). Long-term inpatient stays are now less common due to deinstitutionalization, although still occur. [2] Following (or in lieu of) a hospital admission, support services available can include drop-in centers, visits from members of a community mental health team or Assertive Community Treatment team, supported employment [3] and patient-led support groups. Efforts to avoid repeated hospitalization include the obtaining of community treatment orders which, following judicial approval, coerce the affected individual to receive psychiatric treatment including long-acting injections of anti-psychotic medication. This legal mechanism has been shown to increase the affected patient's time out of the hospital. [4]

Medication

Risperidone (trade name Risperdal) is a common atypical antipsychotic medication. Risperdal tablets.jpg
Risperidone (trade name Risperdal) is a common atypical antipsychotic medication.

The mainstay of treatment for schizophrenia is an antipsychotic medication. [5] Most antipsychotics can take around 7 to 14 days to have their full effect. Medication may improve the positive symptoms of schizophrenia, and social and vocational functioning. [6] However, antipsychotics fail to significantly improve the negative symptoms and cognitive dysfunction. [7] [8] There is evidence of clozapine, amisulpride, olanzapine, and risperidone being the most effective medications. However, a high proportion of studies of risperidone were undertaken by its manufacturer, Janssen-Cilag, and should be interpreted with this in mind. [9] In those on antipsychotics, continued use decreases the risk of relapse. [10] [11] There is little evidence regarding consistent benefits from their use beyond two or three years. [11]

Treatment of schizophrenia changed dramatically in the mid-1950s with the development and introduction of the first antipsychotic chlorpromazine. [12] Others such as haloperidol and trifluoperazine soon followed.

It remains unclear whether the newer antipsychotics reduce the chances of developing neuroleptic malignant syndrome, a rare but serious and potentially fatal neurological disorder most often caused by an adverse reaction to antipsychotics (neuroleptics). [13]

Most people on antipsychotics get side effects. People on typical antipsychotics tend to have a higher rate of extrapyramidal side effects while some atypicals are associated with considerable weight gain, diabetes, and risk of metabolic syndrome; this is most pronounced with olanzapine, while risperidone and quetiapine are also associated with weight gain. [9] Risperidone has a similar rate of extrapyramidal symptoms to haloperidol. [9] The American Psychiatric Association generally recommends that atypicals be used as first line treatment in most patients, but further states that therapy should be individually optimized for each patient. [14]

The response of symptoms to medication is variable; treatment resistant schizophrenia is the failure to respond to two or more antipsychotic medications given in therapeutic doses for six weeks or more. [15] Patients in this category may be prescribed clozapine, a medication that may be more effective at reducing symptoms of schizophrenia, but treatment may come with a higher risk of several potentially lethal side effects including agranulocytosis and myocarditis. [16] [17] Clozapine is the only medication proven to be more effective for people who do not respond to other types of antipsychotics. [18] It also appears to reduce suicide in people with schizophrenia. As clozapine suppresses the development of bone marrow, in turn reducing white blood cells which can lead to infection, blood tests are taken for the first six months on this medication. [19] The risk of experiencing agranulocytosis due to clozapine treatment is higher in elderly people, children, and adolescents. [16] The effectiveness in the studies also needs to be interpreted with caution as the studies may have an increased risk of bias. [16]

Studies have found that antipsychotic treatment following NMS and neutropenia may sometimes be successfully rechallenged (restarted) with clozapine. [20] [21]

Tobacco smoking increases the metabolism of some antipsychotics, by strongly activitating CYP1A2, the enzyme that breaks them down, and a significant difference is found in these levels between smokers and non-smokers. [22] [23] [24] It is recommended that the dosage for those smokers on clozapine be increased by 50%, and for those on olanzapine by 30%. [23] The result of stopping smoking can lead to an increased concentration of the antipsychotic that may result in toxicity, so that monitoring of effects would need to take place with a view to decreasing the dosage; many symptoms may be noticeably worsened, and extreme fatigue, and seizures are also possible with a risk of relapse. Likewise those who resume smoking may need their dosages adjusted accordingly. [22] [25] The altering effects are due to compounds in tobacco smoke and not to nicotine; the use of nicotine replacement therapy therefore has the equivalent effect of stopping smoking and monitoring would still be needed. [22]

Research findings suggested that other neurotransmission systems, including serotonin, glutamate, GABA, and acetylcholine, were implicated in the development of schizophrenia, and that a more inclusive medication was needed. [24] A new first-in-class antipsychotic that targets multiple neurotransmitter systems called lumateperone (ITI-007), was trialed and approved by the FDA in December 2019 for the treatment of schizophrenia in adults. [24] [26] [27] Lumateperone is a small molecule agent that shows improved safety, and tolerance. It interacts with dopamine, serotonin, and glutamate in a complex, uniquely selective manner, and is seen to improve negative and positive symptoms, and social functioning. [28] Lumateperone was also found to reduce potential metabolic dysfunction, have lower rates of movement disorders, and have lower cardiovascular side effects such as a fast heart rate. [24]

The fixed-dose combination medication xanomeline/trospium chloride (Cobenfy) was approved for medical use in the United States in September 2024. [29] [30] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [29]

Add-on agents

Sometimes the use of a second antipsychotic in combination with another is recommended where there has been a poor response. A review of this use found some evidence for an improvement in symptoms but not for relapse or hospitalisation. The use of combination antipsychotics is increasing in spite of limited supporting evidence, with some countries including Finland, France, and the UK recommending its use and others including Canada, Denmark, and Spain in opposition. [31] Anti-inflammatories, anti-depressants, and mood stabilisers are other add-ons used. Other strategies used include ECT, or repetitive transcranial magnetic stimulation (rTMS) but evidence for these is lacking.

Note: Only adjuncts for which at least one double-blind randomized placebo-controlled trial has provided support are listed in this table.

Adjuncts [32] [33] Symptoms against which efficacy is knownNotable adverse effects seen in clinical trialsHighest quality of clinical data availableNNotes
Adjuncts to clozapine [34] [35]
Antipsychotics
Amisulpride GlobalExtrapyramidal side effects (e.g. tremor, dystonia, akathisia, etc.), headache, somnolence, insomnia, elevated serum prolactin, etc.1 DB-RPCTs16Not approved for use in the US or Canada. Approved for use in Australia, Europe and several countries in East Asia. Can prolong the QT interval, some in vivo evidence [36] suggests it may have anti-diabetogenic effects and hence may improve metabolic parameters in patients on clozapine.
Aripiprazole Global, esp. negativeAkathisia1 DB-RPCT61Can also improve metabolic side effects of clozapine (including body weight). Six studies so far; only one negative.
Risperidone GlobalImpaired cognitive functioning, prolactin elevation and hyperglycaemia2 DB-RPCTs, 1 DB-RCT357 (DB-RPCTs) & 24 (DB-RCT)11 studies have been conducted, 5 negative. A meta-analysis [34] found no clinically significant difference between risperidone augmentation and placebo augmentation.
Sulpiride GlobalIncreased serum prolactin1 DB-RPCT28Not approved for use in the US, Canada and Australia.
Ziprasidone Global QTc interval prolongation1 DB-RCT24Was compared with risperidone in the one DB-RCT.
Antidepressants
Citalopram Negative symptomsWell tolerated1 DB-RPCT61Can prolong the QT interval and since clozapine can prolong the QT interval too it is advisable to avoid their concurrent use in patients with cardiovascular risk factors.
Fluvoxamine Negative and depressive symptomsElevated serum levels of clozapine (via inhibition of P450 cytochromes)Open-label studiesNAImproved metabolic parameters
Mirtazapine Negative, depressive and cognitive symptomsWeight gain2 DB-RPCTs (1 negative)805-HT2A/2C/3 & α2 adrenoceptor antagonist
Anticonvulsants
Lamotrigine Negative & depressive symptoms Stevens–Johnson syndrome, toxic epidermal necrolysis, etc.4 DB-RPCTs (2 negative)108Usually a relatively well tolerated anticonvulsant, but because of risk of potentially-fatal dermatologic AEs the dose must be slowly titrated up in order to prevent these AEs. A meta-analysis [34] found that it was ineffective.
Topiramate Negative symptomsCognitive impairment, sedation, asthenia2 DB-RPCTs (1 negative)57Can cause cognitive impairment and hence should probably be avoided in patients with cognitive impairments.
Valproate Reduced anxiety & depressionWeight gain, hair lossOne open-label study comparing it with lithiumNAIncreases the expression of mGluR2 and GAD67 via histone deacetylase (HDAC) inhibition.
Glutamatergic agents [37] [38]
CX-516 GlobalWell tolerated1 DB-RPCT18Statistically significant improvement in total symptoms but no significant improvement in negative and positive symptoms when considered separately.
Memantine GlobalWell tolerated1 DB-RPCT21Statistically significant improvement in negative and total symptomtology.
Other
Lithium GlobalWeight gain, hypersalivation1 DB-RPCT, 1 DB-RCT10 (DB-RPCT), 20 (DB-RCT)Increased risk of neurological side effects such as neuroleptic malignant syndrome.
E-EPA Global (especially negative and cognitive symptoms)Well tolerated3 DB-RPCT (1 negative)131Ester of the omega-3 fatty acid, eicosapentaenoic acid.
Adjuncts to other antipsychotics
Anti-inflammatory agents [39] [40]
Aspirin [41] [42] Global (especially positive symptoms)Well tolerated1 DB-RPCT70Increased risk of bleeding, but seems relatively well tolerated.
Celecoxib Global (especially negative symptoms)Well tolerated3 DB-RPCTs (1 negative)147May increased the risk of cardiovascular events (which is particularly worrisome as schizophrenia patients are a higher risk group for cardiovascular events). Case series (N=2) suggests efficacy in augmenting clozapine.
Minocycline [43] [44] [45] [46] GlobalWell tolerated4 DB-RPCTs164Increased risk of blood dyscarsias.
Omega-3 fatty acids GlobalWell tolerated6 DB-RPCTs (1 negative) [47] 362May have protective effects against depression.
Pregnenolone [48] [49] [50] [51] GlobalWell tolerated3 DB-RPCTs100Levels of this neurosteroid in the body are elevated by clozapine treatment.
Glutamatergics [37] [52]
D-alanine [53] [54] GlobalWell tolerated1 DB-RPCT31A D-amino acid with affinity towards the glycine site on the NMDA receptor.
D-serine Global (especially negative symptoms)Well tolerated4 DB-RPCTs183Affinity towards the glycine site on NMDA receptors. D. Souza 2013, [55] Heresco-Levy 2005, [56] Lane 2005, [57] Lane 2010, [58] Tsai 1999, [59] Weiser 2012 [60]
Glycine Global (predominantly positive symptoms)Well tolerated5 DB-RPCTs219Endogenous NMDA receptor ligand.
N-acetylcysteine [61] Global (especially negative symptoms)Well tolerated3 DB-RPCTs140Cystine and glutathione prodrug. [62] [63] Cystine increases intracellular glutamate levels via the glutamate-cystine anti porter.

Berk 2008, [64] Berk 2011, [65] Carmeli 2012, [66] Lavoie 2008 [67]

Sarcosine Global (especially negative symptoms)Well tolerated3 DB-RPCTs112 GlyT1 antagonist (i.e. glycine reuptake inhibitor). Also known as N-methylglycine. Lane 2005, [57] Lane 2006, [68] Lane 2008, [69] Lane 2010, [58] Tsai 2004 [70]
Cholinergics [71] [38] [72]
Donepezil GlobalWell tolerated6 DB-RPCTs (5 negative; or 12 DB-RPCTs if one includes cross-over trials; 8 negative in total)378, 474 (including cross-over trials)Possesses antidepressant effects according to one trial.
Galantamine CognitionWell tolerated5 DB-RPCTs (1 negative)170Robust nootropic
Rivastigmine CognitionWell tolerated3 DB-RPCTs (all 3 negative; 5 trials including cross-over trials; 4 negative)93, 131 (including cross-over trials)Seems to be a weaker nootropic
Tropisetron† [73] [74] [75] [76] Cognitive and negative symptomsWell tolerated3 DB-RPCTs120Agonist at α7 nAChRs; antagonist at 5-HT3. Expensive (>$20 AUD/tablet).
Antidepressants [77]
Escitalopram† [78] Negative symptomsWell tolerated1 DB-RPCT40May increase risk of QT interval prolongation.
Fluoxetine Negative symptomsWell tolerated4 DB-RPCTs (3 negative)136The safest of antidepressants listed here in overdose. [79] Risk of QT interval prolongation is lower than with escitalopram (but still exists).
Mianserin [80] Negative and cognitive symptomsWell tolerated2 DB-RPCTs48Weight gain, sedation, dry mouth, constipation and dizziness. Blood dyscarsias are a possible adverse effect and both the Australian Medicines Handbook and British National Formulary 65 (BNF 65) recommend regular complete blood counts to be taken. [81] [82]
Mirtazapine [80] Cognition, [83] [84] negative and positive symptoms† [85] Well tolerated≥4 DB-RPCTs (one negative)127Relatively safe in overdose. Produces significant sedation and weight gain, however, which could potentially add to the adverse effects of atypical antipsychotics. Can reduce antipsychotic-induced akathisia. [86]
Ritanserin Negative symptomsWell tolerated2 DB-RPCTs735-HT2A/2C antagonist. Not clinically available.
Trazodone Negative symptomsWell tolerated2 DB-RPCTs725-HT2A antagonist and SSRI. Has sedative effects and hence might exacerbate some of the side effects of atypical antipsychotics.
Other
Alpha-lipoic acid [87] [88] Weight gainWell tolerated1 DB-RPCT360Offset antipsychotic drug-induced weight gain. Increased total antioxidant status. May also increase GSH:GSSG (reduced glutathione:oxidized glutathione) ratio. [89]
L-Theanine [90] [91] [92] Positive, activation, and anxiety symptomsWell tolerated2 DB-RPCTs40 Glutamic acid analog. Primary study noted reduction in positive, activation, and anxiety symptoms. Additional studies have noted improvements in attention. [93] [94] [95] [96] Research suggests that theanime has a regulatory effect on the nicotine acetylcholine receptor-dopamine reward pathway, and was shown to reduced dopamine production in the midbrain of mice. [97]
Famotidine† [98] GlobalWell tolerated1 DB-RPCT30May reduce the absorption of vitamin B12 from the stomach. Might also increase susceptibility to food poisoning.
Ginkgo biloba Tardive dyskinesia, positive symptomsWell tolerated4 DB-RPCTs157Atmaca 2005, [99] Doruk 2008, [100] Zhang 2001, [101] Zhang 2001, [102] Zhang 2006, [103] Zhang 2011, [104] Zhou 1999 [105]
Ondansetron [106] Negative and cognitive symptomsWell tolerated3 DB-RPCTs151 5-HT3 antagonist. May prolong the QT interval. Expensive (>$4 AUD/tablet).
SAM-e [107] AggressionWell tolerated1 DB-RPCT18Study noted improvement of aggressive behavior and quality of life impairment. while in another study SAM-e has been purported to have a contributory effect on psychosis [108]
Vitamin C [109] [110] [111] [112] GlobalWell tolerated1 DB-RPCT40Improves BPRS scores.

Acronyms used:
DB-RPCT — Double-blind randomized placebo-controlled trial.
DB-RCT — Double-blind randomized controlled trial.

Note: Global in the context of schizophrenia symptoms here refers to all four symptom clusters.

N refers to the total sample sizes (including placebo groups) of DB-RCTs.

† No secondary sources could be found on the utility of the drug in question, treating the symptom in question (or any symptom in the case of where † has been placed next to the drug's name).

Psychosocial

Psychotherapy is also widely recommended, though not widely used in the treatment of schizophrenia, due to reimbursement problems or lack of training. As a result, treatment is often confined to psychiatric medication. [113]

Cognitive behavioral therapy (CBT) is used to target specific symptoms and improve related issues such as self-esteem and social functioning. Although the results of early trials were inconclusive [114] as the therapy advanced from its initial applications in the mid-1990s, meta-analytic reviews suggested CBT to be an effective treatment for the psychotic symptoms of schizophrenia. [115] [116] Nonetheless, more recent meta analyses have cast doubt upon the utility of CBT as a treatment for the symptoms of psychosis. [117] [118] [119]

Another approach is cognitive remediation therapy, a technique aimed at remediating the neurocognitive deficits sometimes present in schizophrenia. Based on techniques of neuropsychological rehabilitation, early evidence has shown it to be cognitively effective, resulting in the improvement of previous deficits in psychomotor speed, verbal memory, nonverbal memory, and executive function, such improvements being related to measurable changes in brain activation as measured by fMRI. [120]

Metacognitive training (MCT): In view of many empirical findings [121] suggesting deficits of metacognition (thinking about one's thinking, reflecting upon one's cognitive process) in patients with schizophrenia, metacognitive training (MCT) [121] [122] is increasingly adopted as a complementary treatment approach. MCT aims at sharpening the awareness of patients for a variety of cognitive biases (e.g. jumping to conclusions, attributional biases, over-confidence in errors), which are implicated in the formation and maintenance of schizophrenia positive symptoms (especially delusions), [123] and to ultimately replace these biases with functional cognitive strategies. The training consists of 8 modules and can be obtained cost-free from the internet in 15 languages. [121] [122] Studies confirm the training's feasibility [124] and efficacy in ameliorating positive psychosis symptoms. [125] [126] Studies of single training module show that this intervention target specific cognitive biases. [127] Recently, an individualized format has been developed which combines the metacognitive approach with methods derived from cognitive-behavioral therapy. [128]

Family Therapy or Education, which addresses the whole family system of an individual with a diagnosis of schizophrenia, may be beneficial, at least if the duration of intervention is longer-term. [129] [130] [131] A 2010 Cochrane review concluded that many of the clinical trials that studied the effectiveness of family interventions were poorly designed, and may over estimate the effectiveness of the therapy. High-quality randomized controlled trials in this area are required. [131] Aside from therapy, the impact of schizophrenia on families and the burden on careers has been recognized, with the increasing availability of self-help books on the subject. [132] [133] There is also some evidence for benefits from social skills training, although there have also been significant negative findings. [134] [14] Some studies have explored the possible benefits of music therapy and other creative therapies. [135] [136] [137]

The Soteria model is alternative to inpatient hospitalization using full non professional care and a minimal medication approach. [138] Although evidence is limited, a review found the program equally as effective as treatment with medications but due to the limited evidence did not recommend it as a standard treatment. [139] Training in the detection of subtle facial expressions has been used to improve facial emotional recognition. [140]

Avatar Therapy, developed by Professor Julian Leff, was developed to help patients deal with the impact of auditory hallucinations. In this therapy, patients engage in real-time, face-to-face dialogue with a digital avatar that represents the voice they hear. The therapist operates the avatar, allowing it to verbally communicate with the patient in a controlled and safe environment. Over time, the patient learns to confront and reduce the power of the hallucination, often finding relief from its intensity and frequency. [141] AVATAR therapy aims to help patients gain control over their symptoms, reduce distress, and improve overall mental health. This therapy is grounded in the idea that giving a “face” and voice to auditory hallucinations can help individuals reframe their relationship with these experiences. [142] AVATAR therapy has shown promising results in clinical trials, demonstrating improvements in reducing the impact of auditory hallucinations compared to standard treatment options. A 2020 Cochrane review however failed to find any consistent effects in the reviewed studies. [143]

Supplements

Disruption of the gut microbiota has been linked to inflammation, and disorders of the central nervous system. This includes schizophrenia, and probiotic supplementation has been proposed to improve its symptoms. A review found no evidence to support this but it concludes that probiotics may be of benefit in regulating bowel movements and lessening the metabolic effects of antipsychotics. [144]

A review explains the need for an optimal level of vitamin D and omega-3 fatty acids for the proper synthesis and control of the neurotransmitter serotonin. Serotonin regulates executive function, sensory gating, and social behavior – all of which are commonly impaired in schizophrenia. The model proposed suggests that supplementation would help in preventing and treating these brain dysfunctions. [145] Another review finds that omega-3 fatty acids and vitamin D are among the nutritional factors known to have a beneficial effect on mental health. [146] A Cochrane review found evidence to suggest that the use of omega-3 fatty acids in the prodromal stage may prevent the transition to psychosis but the evidence was poor quality and further studies were called for. [147]

Treatment resistant schizophrenia

About half of those with schizophrenia will respond favourably to antipsychotics, and have a good return of functioning. [148] However, positive symptoms persist in up to a third of people. Following two trials of different antipsychotics over six weeks, that also prove ineffective, they will be classed as having treatment resistant schizophrenia (TRS), and clozapine will be offered. [149] [150] Clozapine is of benefit to around half of this group although it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people. [151] [152] [153] Between 12 and 20 per cent will not respond to clozapine and this group is said to have ultra treatment resistant schizophrenia. [149] [154] ECT may be offered to treat TRS as an add-on therapy, and is shown to sometimes be of benefit. [154] A review concluded that this use only has an effect on medium-term TRS and that there is not enough evidence to support its use other than for this group. [155]

TRS is often accompanied by a low quality of life, and greater social dysfunction. [156] TRS may be the result of inadequate rather than inefficient treatment; it also may be a false label due to medication not being taken regularly, or at all. [157] About 16 per cent of people who had initially been responsive to treatment later develop resistance. This could relate to the length of time on APs, with treatment becoming less responsive. [158] This finding also supports the involvement of dopamine in the development of schizophrenia. [157] Studies suggest that TRS may be a more heritable form. [159]

TRS may be evident from first episode psychosis, or from a relapse. It can vary in its intensity and response to other therapies. [156] This variation is seen to possibly indicate an underlying neurobiology such as dopamine supersensitivity (DSS), glutamate or serotonin dysfunction, inflammation and oxidative stress. [149] Studies have found that dopamine supersensitivity is found in up to 70% of those with TRS. [160] The variation has led to the suggestion that treatment responsive and treatment resistant schizophrenia be considered as two different subtypes. [149] [159] It is further suggested that if the subtypes could be distinguished at an early stage significant implications could follow for treatment considerations, and for research. [154] Neuroimaging studies have found a significant decrease in the volume of grey matter in those with TRS with no such change seen in those who are treatment responsive. [154] In those with ultra treatment resistance the decrease in grey matter volume was larger. [149] [154]

Rehabilitative interventions

Individual Placement and Support (IPS), where the rehabilitated person is directly placed and supported in the workplace with the support of a professional, promotes the employment of people with schizophrenia and their survival in the open labour market better than the model of gradual work practice before placement. [161]

Research evidence on the relative superiority of different types of housing units for people with psychosis in terms of symptomatic or functional development is scarce. The support and independence provided in a residential unit should be flexible, individualised and, as far as possible, at the choice of the person being rehabilitated. The living environment should be as normal as possible and the rehabilitated person should not be isolated from the rest of the community. [162] [163]

Traditional Chinese medicine

Acupuncture is a procedure generally known to be safe and with few adverse effects. A Cochrane review found limited evidence for its possible antipsychotic effects in the treatment of schizophrenia and called for more studies. [164] Another review found limited evidence for its use as an add-on therapy for the relief of symptoms but positive results were found for the treatment of sleep disorders that often accompany schizophrenia. [165]

Wendan decoction is a classic herbal treatment in traditional Chinese medicine used for symptoms of psychosis, and other conditions. Wendan decoction is safe, accessible, and inexpensive, and a Cochrane review was carried out for its possible effects on schizophrenia symptoms. Limited evidence was found for its positive antipsychotic effects in the short term, and it was associated with fewer adverse effects. Used as an add-on to an antipsychotic, wider positive effects were found. Larger studies of improved quality were called for. [166] [167]

Other

Various brain stimulation techniques have been used to treat the positive symptoms of schizophrenia, in particular auditory verbal hallucinations (AVHs), and investigations are ongoing. [168] Most studies focus on transcranial direct-current stimulation (tDCM), and repetitive transcranial magnetic stimulation (rTMS). [169] Transcranial magnetic stimulation is low-cost, noninvasive, and almost free of side-effects making it a good therapeutic choice with promising outcomes. [168] Low-frequency TMS of the left temporoparietal cortex (the region containing Broca's area) can reduce auditory hallucinations. [168] rTMS seems to be the most effective treatment for those with persistent AVHs, as an add-on therapy. [169] AVHs are not resolved in up to 30 per cent of those on antipsychotics and a further percentage still experience only a partial response. [169] Techniques based on focused ultrasound for deep brain stimulation could provide insight for the treatment of AVHs. [169]

An established brain stimulation treatment is electroconvulsive therapy. This is not considered a first-line treatment but may be prescribed in cases where other treatments have failed. It is more effective where symptoms of catatonia are present, [170] and is recommended for use under NICE guidelines in the UK for catatonia if previously effective, though there is no recommendation for use for schizophrenia otherwise. [171] Psychosurgery has now become a rare procedure and is not a recommended treatment for schizophrenia. [172]

A study in 2014 conducted by an Australian researcher indicated that the pericarp powder of Garcinia mangostana L. have the ability to reduce oxidative stress as an effective treatment for schizophrenia. This process includes increasing glutathione S-transferase levels which enhances mitochondrial activity over a period of 180 days under a sustained intake of 1000 mg/day. [173]

There may be some benefit in trying several treatment modalities at the same time, especially those that could be classed as lifestyle interventions. [174] Nidotherapy is suggested to be a cost-effective social prescribing intervention using efforts to change the environment to improve functional ability. [175]

Numerous people diagnosed with schizophrenia have found it necessary to organize confidential groups with each other where they can discuss their experiences without clinicians present. [176] [177] Peer support in which people with experiential knowledge of mental illness provide knowledge, experience, emotional, social or practical help to each other is considered an important aspect of coping with schizophrenia and other serious mental health conditions. A 2019 Cochrane reviews of evidence for peer-support interventions compared to supportive or psychosocial interventions were unable to support or refute the effectiveness of peer-support due to limited data. [178]

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

<span class="mw-page-title-main">Cognitive behavioral therapy</span> Type of therapy to improve mental health

Cognitive behavioral therapy (CBT) is a form of psychotherapy that aims to reduce symptoms of various mental health conditions, primarily depression, PTSD and anxiety disorders. Cognitive behavioral therapy focuses on challenging and changing cognitive distortions and their associated behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. Though it was originally designed to treat depression, its uses have been expanded to include many issues and the treatment of many mental health and other conditions, including anxiety, substance use disorders, marital problems, ADHD, and eating disorders. CBT includes a number of cognitive or behavioral psychotherapies that treat defined psychopathologies using evidence-based techniques and strategies.

<span class="mw-page-title-main">Schizophrenia</span> Mental disorder with psychotic symptoms

Schizophrenia is a mental disorder characterized variously by hallucinations, delusions, disorganized thinking and behavior, and flat or inappropriate affect. Symptoms develop gradually and typically begin during young adulthood and are never resolved. There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person. For a diagnosis of schizophrenia, the described symptoms need to have been present for at least six months or one month. Many people with schizophrenia have other mental disorders, especially mood disorders, anxiety disorders, and obsessive–compulsive disorder.

<span class="mw-page-title-main">Clozapine</span> Atypical antipsychotic medication

Clozapine, sold under the brand name Clozaril among others, is a psychiatric medication and was the first atypical antipsychotic to be discovered. It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics, or who have been unable to tolerate other drugs due to extrapyramidal side effects. In the US the FDA authorisation also includes use for people with recurrent suicidal behaviour in people with schizophrenia or schizoaffective disorder. It is also used for the treatment of psychosis in Parkinson's disease.

<span class="mw-page-title-main">Trifluoperazine</span> Typical antipsychotic medication

Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Risperidone</span> Antipsychotic medication

Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder, as well as irritability associated with autism. It is taken either by mouth or by injection. The injectable versions are long-acting and last for 2–4 weeks.

<span class="mw-page-title-main">Quetiapine</span> Atypical antipsychotic medication

Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Despite being widely used as a sleep aid, the benefits of such use may not outweigh the risk of undesirable side effects. It is taken orally.

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting and as an appetite stimulant. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

<span class="mw-page-title-main">Tardive dyskinesia</span> Neurological disorder featuring involuntary, repetitive body movements

Tardive dyskinesia (TD) is an iatrogenic disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips, which occurs following treatment with medication. Additional motor symptoms include chorea or athetosis. In about 20% of people with TD, the disorder interferes with daily functioning. If TD is present in the setting of a long-term drug therapy, reversibility can be determined primarily by severity of symptoms and how long symptoms have been present before the long-term drug has been stopped.

<span class="mw-page-title-main">Loxapine</span> Antipsychotic medication

Loxapine, sold under the brand names Loxitane and Adasuve among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia. The medicine is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.

<span class="mw-page-title-main">Azapirone</span> Drug class of psycotropic drugs

Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

Treatment-resistant depression (TRD) is major depressive disorder in which an affected person does not respond adequately to at least two different antidepressant medications at an adequate dose and for an adequate duration. Inadequate response has most commonly been defined as less than 25% reduction in depressive symptoms following treatment with an antidepressant. Many clinicians and researchers question the construct validity and clinical utility of treatment-resistant depression as currently conceptualized.

<span class="mw-page-title-main">Sulpiride</span> Atypical antipsychotic

Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and is sometimes used in low dosage to treat anxiety and mild depression.

The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.

<span class="mw-page-title-main">Asenapine</span> Medication to treat schizophrenia

Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

<span class="mw-page-title-main">Clotiapine</span> Antipsychotic medication

Clotiapine (Entumine) is an atypical antipsychotic of the dibenzothiazepine chemical class. It was first introduced in a few European countries, Argentina, Taiwan and Israel in 1970.

References

  1. ↑ "Psychosis and schizophrenia in adults: treatment and management | Key-priorities-for-implementation | Guidance and guidelines". The United Kingdom National Institute for Health and Care Excellence (NICE). 12 February 2014.
  2. ↑ Becker T, Kilian R (2006). "Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?". Acta Psychiatrica Scandinavica. Supplementum. 113 (429): 9–16. doi:10.1111/j.1600-0447.2005.00711.x. PMID   16445476. S2CID   34615961.
  3. ↑ McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (March 2007). "Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial". The American Journal of Psychiatry. 164 (3): 437–41. doi:10.1176/appi.ajp.164.3.437. PMID   17329468.
  4. ↑ Frank D, Perry JC, Kean D, Sigman M, Geagea K (July 2005). "Effects of compulsory treatment orders on time to hospital readmission". Psychiatric Services. 56 (7). Washington, D.C.: 867–9. doi:10.1176/appi.ps.56.7.867. PMID   16020822.
  5. ↑ National Collaborating Centre for Mental Health; National Institute for Clinical Excellence (2003). Schizophrenia : full national clinical guideline on core interventions in primary and secondary care. London: Gaskell, Royal College of Psychiatrists. ISBN   978-1-901242-97-3. Archived from the original on 2007-09-27.
  6. ↑ Eiring Ø, Landmark BF, Aas E, Salkeld G, Nylenna M, Nytrøen K (April 2015). "What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders". BMJ Open. 5 (4): e007848. doi:10.1136/bmjopen-2015-007848. PMC   4390680 . PMID   25854979.
  7. ↑ Smith T, Weston C, Lieberman J (August 2010). "Schizophrenia (maintenance treatment)". American Family Physician. 82 (4): 338–9. PMID   20704164.
  8. ↑ Tandon R, Keshavan MS, Nasrallah HA (March 2008). "Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview". Schizophrenia Research. 100 (1–3): 4–19. doi:10.1016/j.schres.2008.01.022. PMID   18291627. S2CID   14598183.
  9. 1 2 3 Barry SJ, Gaughan TM, Hunter R (June 2012). "Schizophrenia". BMJ Clinical Evidence. 2012. PMC   3385413 . PMID   23870705. Archived from the original on 2014-09-11.
  10. ↑ Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (June 2012). "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis". Lancet. 379 (9831): 2063–71. doi:10.1016/S0140-6736(12)60239-6. PMID   22560607. S2CID   2018124.
  11. 1 2 Harrow M, Jobe TH (September 2013). "Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?". Schizophrenia Bulletin. 39 (5): 962–5. doi:10.1093/schbul/sbt034. PMC   3756791 . PMID   23512950.
  12. ↑ Turner T (January 2007). "Chlorpromazine: unlocking psychosis". BMJ. 334 (Suppl 1): s7. doi:10.1136/bmj.39034.609074.94. PMID   17204765. S2CID   33739419.
  13. ↑ Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (April 2004). "Neuroleptic malignant syndrome and atypical antipsychotic drugs". The Journal of Clinical Psychiatry. 65 (4): 464–70. doi:10.4088/JCP.v65n0403. PMID   15119907. S2CID   32752143.
  14. 1 2 Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. (February 2004). "Practice Guideline for the Treatment of Patients With Schizophrenia". American Journal of Psychiatry. 161 (2 supplement) (2nd ed.). American Psychological Association (APA). Archived from the original on 2014-03-06.
  15. ↑ Semple D, Smyth R (July 2019). Oxford Handbook of Psychiatry. Oxford University Press. p. 207. ISBN   978-0-19-251496-7.
  16. 1 2 3 Essali A, Al-Haj Haasan N, Li C, Rathbone J (January 2009). "Clozapine versus typical neuroleptic medication for schizophrenia". The Cochrane Database of Systematic Reviews. 2009 (1): CD000059. doi:10.1002/14651858.cd000059.pub2. PMC   7065592 . PMID   19160174.
  17. ↑ Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, et al. (2007). "Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003". Drug Safety. 30 (1): 47–57. doi:10.2165/00002018-200730010-00005. PMID   17194170. S2CID   1153693.
  18. ↑ Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators) (September 2005). "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". The New England Journal of Medicine. 353 (12): 1209–23. doi: 10.1056/NEJMoa051688 . PMID   16172203. S2CID   22499842.
  19. ↑ Kozier B, Erb G, Olivieri R, Snyder S, Lake R, Harvey S (2008). "Chapter 10: Mental health". Fundamentals of Nursing: Concepts, Process and Practice (1st adaptation ed.). Harlow, England: Pearson Education. p. 189. ISBN   978-0-13-197653-5.
  20. ↑ Manu P, Lapitskaya Y, Shaikh A, Nielsen J (2018). "Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases". American Journal of Therapeutics. 25 (2): e218–e223. doi: 10.1097/MJT.0000000000000715 . PMID   29505490. S2CID   3689529.
  21. ↑ Lally J, McCaffrey C, O Murchu C, et al. (July 2019). "Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review". Journal of Clinical Psychopharmacology. 39 (4): 372–379. doi:10.1097/JCP.0000000000001048. PMID   31205196. S2CID   189945135.
  22. 1 2 3 Cather C, Pachas GN, Cieslak KM, Evins AE (June 2017). "Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations". CNS Drugs. 31 (6): 471–481. doi:10.1007/s40263-017-0438-8. PMC   5646360 . PMID   28550660.
  23. 1 2 Tsuda Y, Saruwatari J, Yasui-Furukori N (4 March 2014). "Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine". BMJ Open. 4 (3): e004216. doi:10.1136/bmjopen-2013-004216. PMC   3948577 . PMID   24595134.
  24. 1 2 3 4 Li P, Snyder GL, Vanover KE (2016). "Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future". Current Topics in Medicinal Chemistry. 16 (29): 3385–3403. doi:10.2174/1568026616666160608084834. PMC   5112764 . PMID   27291902.
  25. ↑ Lowe EJ, Ackman ML (April 2010). "Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment". The Annals of Pharmacotherapy. 44 (4): 727–32. doi:10.1345/aph.1M398. PMID   20233914. S2CID   11456024.
  26. ↑ "FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults". drugs.com. 23 December 2019.
  27. ↑ Blair HA (14 February 2020). "Lumateperone: First Approval". Drugs. 80 (4): 417–423. doi:10.1007/s40265-020-01271-6. PMID   32060882. S2CID   211110160.
  28. ↑ Edinoff A, Wu N, deBoisblanc C, et al. (September 2020). "Lumateperone for the Treatment of Schizophrenia". Psychopharmacol Bull. 50 (4): 32–59. PMC   7511146 . PMID   33012872.
  29. 1 2 "FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia". U.S. Food and Drug Administration (FDA) (Press release). 26 September 2024. Archived from the original on 27 September 2024. Retrieved 27 September 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  30. ↑ "U.S. Food and Drug Administration Approves Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults" (Press release). Bristol Myers Squibb. 27 September 2024. Retrieved 27 September 2024– via Business Wire.
  31. ↑ Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE (June 2017). "Antipsychotic combinations for schizophrenia". The Cochrane Database of Systematic Reviews (Review). 6 (10): CD009005. doi:10.1002/14651858.CD009005.pub2. PMC   6481822 . PMID   28658515.
  32. ↑ Ritsner MS (2013). Ritsner MS (ed.). Polypharmacy in Psychiatry Practice, Volume I. Springer Science+Business Media Dordrecht. doi:10.1007/978-94-007-5805-6. ISBN   9789400758056. S2CID   7705779.
  33. ↑ Ritsner MS (2013). Ritsner MS (ed.). Polypharmacy in Psychiatry Practice, Volume II. Springer Science+Business Media Dordrecht. doi:10.1007/978-94-007-5799-8. ISBN   9789400757998. S2CID   2077519.
  34. 1 2 3 Porcelli S, Balzarro B, Serretti A (March 2012). "Clozapine resistance: augmentation strategies". European Neuropsychopharmacology. 22 (3): 165–82. doi:10.1016/j.euroneuro.2011.08.005. PMID   21906915. S2CID   39716777.
  35. ↑ Sommer IE, Begemann MJ, Temmerman A, Leucht S (September 2012). "Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review". Schizophrenia Bulletin. 38 (5): 1003–11. doi:10.1093/schbul/sbr004. PMC   3446238 . PMID   21422107.
  36. ↑ Roix JJ, DeCrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R (April 2012). "Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion". Diabetes, Obesity & Metabolism. 14 (4): 329–34. doi:10.1111/j.1463-1326.2011.01529.x. PMID   22059694. S2CID   28553141.
  37. 1 2 Singh SP, Singh V (October 2011). "Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia". CNS Drugs. 25 (10): 859–85. doi:10.2165/11586650-000000000-00000. PMID   21936588. S2CID   207299820.
  38. 1 2 Choi KH, Wykes T, Kurtz MM (September 2013). "Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy". The British Journal of Psychiatry. 203 (3): 172–8. doi:10.1192/bjp.bp.111.107359. PMC   3759029 . PMID   23999481.
  39. ↑ Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL (April 2013). "A review of anti-inflammatory agents for symptoms of schizophrenia". Journal of Psychopharmacology. 27 (4): 337–42. doi:10.1177/0269881112467089. PMC   3641824 . PMID   23151612.
  40. ↑ Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS (January 2014). "Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update". Schizophrenia Bulletin. 40 (1): 181–91. doi:10.1093/schbul/sbt139. PMC   3885306 . PMID   24106335.
  41. ↑ Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (May 2010). "Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial". The Journal of Clinical Psychiatry. 71 (5): 520–7. doi:10.4088/JCP.09m05117yel. hdl:11370/5644f8cd-b8ea-4ecc-9755-0f7c9ed86d02. PMID   20492850.
  42. ↑ Schmidt L, Phelps E, Friedel J, Shokraneh F (August 2019). "Acetylsalicylic acid (aspirin) for schizophrenia". The Cochrane Database of Systematic Reviews. 2019 (8): CD012116. doi:10.1002/14651858.CD012116.pub2. PMC   6699651 . PMID   31425623.
  43. ↑ Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, et al. (March 2014). "Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial". Schizophrenia Research. 153 (1–3): 169–76. doi:10.1016/j.schres.2014.01.011. PMID   24503176. S2CID   5908680.
  44. ↑ Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, et al. (March 2014). "Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study". Psychiatry Research. 215 (3): 540–6. doi:10.1016/j.psychres.2013.12.051. PMID   24480077. S2CID   5442977.
  45. ↑ Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. (September 2012). "Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment". Journal of Psychopharmacology. 26 (9): 1185–93. doi:10.1177/0269881112444941. PMID   22526685. S2CID   19246435.
  46. ↑ Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. (February 2010). "A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia". The Journal of Clinical Psychiatry. 71 (2): 138–49. doi:10.4088/JCP.08m04666yel. PMID   19895780. S2CID   10554795.
  47. ↑ Joy CB, Mumby-Croft R, Joy LA (July 2006). "Polyunsaturated fatty acid supplementation for schizophrenia". The Cochrane Database of Systematic Reviews. 2006 (3): CD001257. doi:10.1002/14651858.CD001257.pub2. PMC   7032618 . PMID   16855961.
  48. ↑ Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, et al. (October 2010). "Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial". The Journal of Clinical Psychiatry. 71 (10): 1351–62. doi:10.4088/JCP.09m05031yel. PMID   20584515. S2CID   25628072.
  49. ↑ Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, et al. (July 2009). "Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia". Neuropsychopharmacology. 34 (8): 1885–903. doi:10.1038/npp.2009.26. PMC   3427920 . PMID   19339966.
  50. ↑ Wong P, Chang CC, Marx CE, Caron MG, Wetsel WC, Zhang X (2012). Hashimoto K (ed.). "Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice". PLOS ONE. 7 (12): e51455. Bibcode:2012PLoSO...751455W. doi: 10.1371/journal.pone.0051455 . PMC   3519851 . PMID   23240026.
  51. ↑ Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, et al. (June 2006). "Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics". Neuropsychopharmacology. 31 (6): 1249–63. doi: 10.1038/sj.npp.1300952 . PMID   16319920. S2CID   2499760.
  52. ↑ Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D (September 2012). "Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia". Schizophrenia Bulletin. 38 (5): 958–66. doi:10.1093/schbul/sbs069. PMC   3446214 . PMID   22987851.
  53. ↑ Hatano T, Ohnuma T, Sakai Y, Shibata N, Maeshima H, Hanzawa R, et al. (May 2010). "Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP)". Psychiatry Research. 177 (1–2): 27–31. doi:10.1016/j.psychres.2010.02.014. PMID   20226539. S2CID   10174006.
  54. ↑ Tsai GE, Yang P, Chang YC, Chong MY (February 2006). "D-alanine added to antipsychotics for the treatment of schizophrenia". Biological Psychiatry. 59 (3): 230–4. doi:10.1016/j.biopsych.2005.06.032. PMID   16154544. S2CID   19372446.
  55. ↑ D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, et al. (February 2013). "Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study". Neuropsychopharmacology. 38 (3): 492–503. doi:10.1038/npp.2012.208. PMC   3547200 . PMID   23093223.
  56. ↑ Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. (March 2005). "D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia". Biological Psychiatry. 57 (6): 577–85. doi:10.1016/j.biopsych.2004.12.037. PMID   15780844. S2CID   46348188.
  57. 1 2 Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE (November 2005). "Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study". Archives of General Psychiatry. 62 (11): 1196–204. doi:10.1001/archpsyc.62.11.1196. PMID   16275807.
  58. 1 2 Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE (May 2010). "A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia". The International Journal of Neuropsychopharmacology. 13 (4): 451–60. doi: 10.1017/S1461145709990939 . PMID   19887019.
  59. ↑ Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT (November 1999). "D-serine added to clozapine for the treatment of schizophrenia". The American Journal of Psychiatry. 156 (11): 1822–5. doi:10.1176/ajp.156.11.1822. PMID   10553752. S2CID   29054148.
  60. ↑ Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, et al. (June 2012). "A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia". The Journal of Clinical Psychiatry. 73 (6): e728-34. doi:10.4088/JCP.11m07031. PMID   22795211.
  61. ↑ Dean O, Giorlando F, Berk M (March 2011). "N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action". Journal of Psychiatry & Neuroscience. 36 (2): 78–86. doi:10.1503/jpn.100057. PMC   3044191 . PMID   21118657.
  62. ↑ Aoyama K, Watabe M, Nakaki T (November 2008). "Regulation of neuronal glutathione synthesis". Journal of Pharmacological Sciences. 108 (3): 227–38. doi: 10.1254/jphs.08R01CR . PMID   19008644.
  63. ↑ Jain A, Mårtensson J, Stole E, Auld PA, Meister A (March 1991). "Glutathione deficiency leads to mitochondrial damage in brain". Proceedings of the National Academy of Sciences of the United States of America. 88 (5): 1913–7. Bibcode:1991PNAS...88.1913J. doi: 10.1073/pnas.88.5.1913 . PMC   51136 . PMID   2000395.
  64. ↑ Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. (September 2008). "N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial". Biological Psychiatry. 64 (5): 361–8. doi:10.1016/j.biopsych.2008.03.004. PMID   18436195. S2CID   10321144.
  65. ↑ Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, et al. (July 2011). "Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia". The Journal of Clinical Psychiatry. 72 (7): 909–13. doi:10.4088/JCP.09m05741yel. PMID   20868637.
  66. ↑ Carmeli C, Knyazeva MG, Cuénod M, Do KQ (2012). Burne T (ed.). "Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial". PLOS ONE. 7 (2): e29341. Bibcode:2012PLoSO...729341C. doi: 10.1371/journal.pone.0029341 . PMC   3285150 . PMID   22383949.
  67. ↑ Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. (August 2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology. 33 (9): 2187–99. doi: 10.1038/sj.npp.1301624 . hdl: 10536/DRO/DU:30071388 . PMID   18004285. S2CID   237232.
  68. ↑ Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, et al. (September 2006). "Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia". Biological Psychiatry. 60 (6): 645–9. doi:10.1016/j.biopsych.2006.04.005. PMID   16780811. S2CID   42741531.
  69. ↑ Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE (January 2008). "Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study". Biological Psychiatry. 63 (1): 9–12. doi:10.1016/j.biopsych.2007.04.038. PMID   17659263. S2CID   26037874.
  70. ↑ Tsai G, Lane HY, Yang P, Chong MY, Lange N (March 2004). "Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia". Biological Psychiatry. 55 (5): 452–6. doi:10.1016/j.biopsych.2003.09.012. PMID   15023571. S2CID   35723786.
  71. ↑ Singh J, Kour K, Jayaram MB (January 2012). "Acetylcholinesterase inhibitors for schizophrenia". The Cochrane Database of Systematic Reviews. 1 (1): CD007967. doi:10.1002/14651858.CD007967.pub2. PMC   6823258 . PMID   22258978.
  72. ↑ Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM (April 2010). "Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature". CNS Drugs. 24 (4): 303–17. doi:10.2165/11530260-000000000-00000. PMID   20297855. S2CID   45807136.
  73. ↑ Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, et al. (July 2005). "Tropisetron improves deficits in auditory P50 suppression in schizophrenia". Schizophrenia Research. 76 (1): 67–72. doi:10.1016/j.schres.2004.12.016. PMID   15927799. S2CID   25260365.
  74. ↑ Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, et al. (June 2010). "A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia". Annals of General Psychiatry. 9 (1): 27. doi: 10.1186/1744-859X-9-27 . PMC   2901366 . PMID   20573264.
  75. ↑ Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, et al. (September 2012). "Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia". The American Journal of Psychiatry. 169 (9): 974–81. doi:10.1176/appi.ajp.2012.11081289. PMID   22952075.
  76. ↑ Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, et al. (August 2013). "A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia". Psychopharmacology. 228 (4): 595–602. doi:10.1007/s00213-013-3064-2. PMID   23515583. S2CID   15652697.
  77. ↑ Singh SP, Singh V, Kar N, Chan K (September 2010). "Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis". The British Journal of Psychiatry. 197 (3): 174–9. doi: 10.1192/bjp.bp.109.067710 . PMID   20807960.
  78. ↑ Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K (August 2010). "Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial". Psychiatry Research. 179 (1): 19–23. doi:10.1016/j.psychres.2010.04.035. PMID   20472299. S2CID   261170.
  79. ↑ White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–50. doi:10.1007/BF03161207. PMC   3550116 . PMID   19031375.
  80. 1 2 Hecht EM, Landy DC (February 2012). "Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis". Schizophrenia Research. 134 (2–3): 202–6. doi:10.1016/j.schres.2011.11.030. PMID   22169246. S2CID   36119981.
  81. ↑ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  82. ↑ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. p.  247. ISBN   978-0-85711-084-8.
  83. ↑ Ritsner MS (2013). Ritsner MS (ed.). Polypharmacy in Psychiatry Practice, Volume I. Springer Science+Business Media Dordrecht. doi:10.1007/978-94-007-5805-6. ISBN   9789400758056. S2CID   7705779.
  84. ↑ Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S (March 2013). "Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia". Clinical Schizophrenia & Related Psychoses. 9 (2): 88–95. doi:10.3371/CSRP.VIRE.030813. PMID   23491969.
  85. ↑ Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G (June 2011). "More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 35 (4): 1080–6. doi:10.1016/j.pnpbp.2011.03.004. PMID   21402120. S2CID   37328991.
  86. ↑ Kumar R, Sachdev PS (May 2009). "Akathisia and second-generation antipsychotic drugs". Current Opinion in Psychiatry. 22 (3): 293–99. doi:10.1097/YCO.0b013e32832a16da. PMID   19378382. S2CID   31506138.
  87. ↑ Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, et al. (January 2011). "Effects of alpha-lipoic Acid on body weight in obese subjects". The American Journal of Medicine. 124 (1): 85.e1–8. doi:10.1016/j.amjmed.2010.08.005. PMID   21187189.
  88. ↑ Kim E, Park DW, Choi SH, Kim JJ, Cho HS (April 2008). "A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia". Journal of Clinical Psychopharmacology. 28 (2): 138–46. doi:10.1097/JCP.0b013e31816777f7. PMID   18344723. S2CID   7873991.
  89. ↑ Jariwalla RJ, Lalezari J, Cenko D, Mansour SE, Kumar A, Gangapurkar B, Nakamura D (March 2008). "Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection". Journal of Alternative and Complementary Medicine. 14 (2): 139–46. doi:10.1089/acm.2006.6397. PMID   18315507.
  90. ↑ Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V (January 2011). "L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study". The Journal of Clinical Psychiatry. 72 (1): 34–42. doi:10.4088/JCP.09m05324gre. PMID   21208586. S2CID   4937207.
  91. ↑ Miodownik C, Maayan R, Ratner Y, Lerner V, Pintov L, Mar M, et al. (2011). "Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients". Clinical Neuropharmacology. 34 (4): 155–60. doi:10.1097/WNF.0b013e318220d8c6. PMID   21617527. S2CID   9786949.
  92. ↑ Lardner AL (July 2014). "Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders". Nutritional Neuroscience. 17 (4): 145–55. doi:10.1179/1476830513Y.0000000079. PMID   23883567. S2CID   206849271.
  93. ↑ Kelly SP, Gomez-Ramirez M, Montesi JL, Foxe JJ (August 2008). "L-theanine and caffeine in combination affect human cognition as evidenced by oscillatory alpha-band activity and attention task performance". The Journal of Nutrition. 138 (8): 1572S–1577S. doi: 10.1093/jn/138.8.1572S . PMID   18641209.
  94. ↑ Park SK, Jung IC, Lee WK, Lee YS, Park HK, Go HJ, et al. (April 2011). "A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study". Journal of Medicinal Food. 14 (4): 334–43. doi:10.1089/jmf.2009.1374. PMID   21303262. S2CID   19296401.
  95. ↑ Foxe JJ, Morie KP, Laud PJ, Rowson MJ, de Bruin EA, Kelly SP (June 2012). "Assessing the effects of caffeine and theanine on the maintenance of vigilance during a sustained attention task". Neuropharmacology. 62 (7): 2320–7. doi:10.1016/j.neuropharm.2012.01.020. PMID   22326943. S2CID   13232338.
  96. ↑ Nobre AC, Rao A, Owen GN (2008). "L-theanine, a natural constituent in tea, and its effect on mental state". Asia Pacific Journal of Clinical Nutrition. 17 (Suppl 1): 167–8. PMID   18296328.
  97. ↑ Di X, Yan J, Zhao Y, Chang Y, Zhao B (December 2012). "L-theanine inhibits nicotine-induced dependence via regulation of the nicotine acetylcholine receptor-dopamine reward pathway". Science China Life Sciences. 55 (12): 1064–74. doi: 10.1007/s11427-012-4401-0 . PMID   23233221. S2CID   17803427.
  98. ↑ Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J (August 2013). "A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia". Journal of Clinical Psychopharmacology. 33 (4): 472–8. doi:10.1097/JCP.0b013e3182970490. PMID   23764683. S2CID   13048121.
  99. ↑ Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Kirtas O (December 2005). "The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia". Psychiatry and Clinical Neurosciences. 59 (6): 652–6. doi: 10.1111/j.1440-1819.2005.01432.x . PMID   16401239. S2CID   1892988.
  100. ↑ Doruk A, Uzun O, Ozşahin A (July 2008). "A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia". International Clinical Psychopharmacology. 23 (4): 223–7. doi:10.1097/YIC.0b013e3282fcff2f. PMID   18545061. S2CID   42478246.
  101. ↑ Zhang XY, Zhou DF, Su JM, Zhang PY (February 2001). "The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia". Journal of Clinical Psychopharmacology. 21 (1): 85–8. doi:10.1097/00004714-200102000-00015. PMID   11199954. S2CID   7836683.
  102. ↑ Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY (November 2001). "A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia". The Journal of Clinical Psychiatry. 62 (11): 878–83. doi:10.4088/JCP.v62n1107. PMID   11775047.
  103. ↑ Zhang XY, Zhou DF, Cao LY, Wu GY (September 2006). "The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial". Psychopharmacology. 188 (1): 12–7. doi:10.1007/s00213-006-0476-2. PMID   16906395. S2CID   12411168.
  104. ↑ Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF (May 2011). "Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial". The Journal of Clinical Psychiatry. 72 (5): 615–21. doi:10.4088/JCP.09m05125yel. PMID   20868638. S2CID   37085462.
  105. ↑ Zhou D, Zhang X, Su J, Nan Z, Cui Y, Liu J, et al. (December 1999). "The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia". Chinese Medical Journal. 112 (12): 1093–6. PMID   11721446.
  106. ↑ Bennett AC, Vila TM (July–August 2010). "The role of ondansetron in the treatment of schizophrenia". The Annals of Pharmacotherapy. 44 (7–8): 1301–6. doi:10.1345/aph.1P008. PMID   20516364. S2CID   21574153.
  107. ↑ Strous RD, Ritsner MS, Adler S, Ratner Y, Maayan R, Kotler M, et al. (January 2009). "Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia". European Neuropsychopharmacology. 19 (1): 14–22. doi:10.1016/j.euroneuro.2008.08.004. PMID   18824331. S2CID   207712279.
  108. ↑ Guidotti A, Ruzicka W, Grayson DR, Veldic M, Pinna G, Davis JM, Costa E (January 2007). "S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis". NeuroReport. 18 (1): 57–60. doi:10.1097/WNR.0b013e32800fefd7. PMID   17259861. S2CID   25378736.
  109. ↑ Dakhale GN, Khanzode SD, Khanzode SS, Saoji A (November 2005). "Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia". Psychopharmacology. 182 (4): 494–8. doi:10.1007/s00213-005-0117-1. PMID   16133138. S2CID   24917071.
  110. ↑ Wang Y, Liu XJ, Robitaille L, Eintracht S, MacNamara E, Hoffer LJ (September 2013). "Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients". The American Journal of Clinical Nutrition. 98 (3): 705–11. doi: 10.3945/ajcn.112.056366 . PMID   23885048.
  111. ↑ Zhang M, Robitaille L, Eintracht S, Hoffer LJ (May 2011). "Vitamin C provision improves mood in acutely hospitalized patients". Nutrition. 27 (5): 530–3. doi:10.1016/j.nut.2010.05.016. PMID   20688474.
  112. ↑ Kennedy DO, Veasey R, Watson A, Dodd F, Jones E, Maggini S, Haskell CF (July 2010). "Effects of high-dose B vitamin complex with vitamin C and minerals on subjective mood and performance in healthy males". Psychopharmacology. 211 (1): 55–68. doi:10.1007/s00213-010-1870-3. PMC   2885294 . PMID   20454891.
  113. ↑ Moran M (18 November 2005). "Psychosocial Treatment Often Missing From Schizophrenia Regimens". Psychiatric News. 40 (22): 24–37. doi:10.1176/pn.40.22.0024b.
  114. ↑ Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C (October 2004). Jones C (ed.). "Cognitive behaviour therapy for schizophrenia". The Cochrane Database of Systematic Reviews (4): CD000524. doi:10.1002/14651858.CD000524.pub2. PMID   15495000. (Retracted, see doi:10.1002/14651858.CD000524.pub3, PMID   21491377)
  115. ↑ Wykes T, Steel C, Everitt B, Tarrier N (May 2008). "Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor". Schizophrenia Bulletin. 34 (3): 523–37. doi:10.1093/schbul/sbm114. PMC   2632426 . PMID   17962231.
  116. ↑ Zimmermann G, Favrod J, Trieu VH, Pomini V (September 2005). "The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis". Schizophrenia Research. 77 (1): 1–9. doi:10.1016/j.schres.2005.02.018. PMID   16005380. S2CID   31560136.
  117. ↑ Lynch D, Laws KR, McKenna PJ (January 2010). "Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials". Psychological Medicine. 40 (1): 9–24. doi: 10.1017/s003329170900590x . hdl: 2299/5741 . PMID   19476688. S2CID   1001891.
  118. ↑ Newton‐Howes, Giles and Rebecca Wood. "Cognitive behavioural therapy and the psychopathology of schizophrenia: Systematic review and meta‐analysis." Psychology and Psychotherapy: Theory, Research and Practice (2011).
  119. ↑ Jones C, Hacker D, Meaden A, Cormac I, Irving CB (April 2011). "WITHDRAWN: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia". The Cochrane Database of Systematic Reviews (4): CD000524. doi:10.1002/14651858.cd000524.pub3. PMID   21491377.
  120. ↑ Wykes T, Brammer M, Mellers J, Bray P, Reeder C, Williams C, Corner J (August 2002). "Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia". The British Journal of Psychiatry. 181: 144–52. doi: 10.1192/bjp.181.2.144 . PMID   12151286. S2CID   221295938.
  121. 1 2 3 Moritz S, Woodward TS (November 2007). "Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention". Current Opinion in Psychiatry. 20 (6): 619–25. doi:10.1097/YCO.0b013e3282f0b8ed. PMID   17921766. S2CID   3193086.
  122. 1 2 Moritz S, Woodward TS, Burlon M (2005). "Metacognitive skill training for patients with schizophrenia (MCT)" (PDF). Hamburg: VanHam Campus. Retrieved 1 April 2011.{{cite journal}}: Cite journal requires |journal= (help)
  123. ↑ Bell V, Halligan PW, Ellis HD (May 2006). "Explaining delusions: a cognitive perspective". Trends in Cognitive Sciences. 10 (5): 219–26. doi:10.1016/j.tics.2006.03.004. PMID   16600666. S2CID   24541273.
  124. ↑ Moritz S, Woodward TS (2007). "Metacognitive training for schizophrenia patients (MCT): A pilot study on feasibility, treatment adherence, and subjective efficacy" (PDF). German Journal of Psychiatry. 10: 69–78. Archived from the original (PDF) on 2016-03-05. Retrieved 2011-04-01.
  125. ↑ Pankowski D, Kowalski J, Gawęda Ł (2016). "The effectiveness of metacognitive training for patients with schizophrenia: a narrative systematic review of studies published between 2009 and 2015". Psychiatria Polska (in Polish). 50 (4): 787–803. doi: 10.12740/pp/59113 . PMID   27847929.
  126. ↑ Eichner C, Berna F (July 2016). "Acceptance and Efficacy of Metacognitive Training (MCT) on Positive Symptoms and Delusions in Patients With Schizophrenia: A Meta-analysis Taking Into Account Important Moderators". Schizophrenia Bulletin. 42 (4): 952–62. doi:10.1093/schbul/sbv225. PMC   4903058 . PMID   26748396.
  127. ↑ Kowalski J, Pankowski D, Lew-Starowicz M, Gawęda Ł (2017-07-03). "Do specific metacognitive training modules lead to specific cognitive changes among patients diagnosed with schizophrenia? A single module effectiveness pilot study". Psychosis. 9 (3): 254–259. doi:10.1080/17522439.2017.1300186. ISSN   1752-2439. S2CID   151353395.
  128. ↑ Moritz S, Veckenstedt R, Randjbar S, Vitzthum F (in press). "Individualized metacognitive therapy for people with schizophrenia psychosis (MCT+)", Springer, Heidelberg. [ clarification needed ]
  129. ↑ McFarlane WR, Dixon L, Lukens E, Lucksted A (April 2003). "Family psychoeducation and schizophrenia: a review of the literature". Journal of Marital and Family Therapy. 29 (2): 223–45. doi:10.1111/j.1752-0606.2003.tb01202.x. PMID   12728780.
  130. ↑ Glynn SM, Cohen AN, Niv N (January 2007). "New challenges in family interventions for schizophrenia". Expert Review of Neurotherapeutics. 7 (1): 33–43. doi:10.1586/14737175.7.1.33. PMID   17187495. S2CID   25863992.
  131. 1 2 Pharoah F, Mari J, Rathbone J, Wong W (December 2010). Pharoah F (ed.). "Family intervention for schizophrenia". The Cochrane Database of Systematic Reviews (12): CD000088. doi:10.1002/14651858.CD000088.pub2. PMC   4204509 . PMID   21154340.
  132. ↑ Jones S, Hayward P (2004). Coping with Schizophrenia: A Guide for Patients, Families and Caregivers . Oxford, England: Oneworld Pub. ISBN   978-1-85168-344-4.
  133. ↑ Torrey EF (2006). Surviving Schizophrenia: A Manual for Families, Consumers, and Providers (5th ed.). HarperCollins. ISBN   978-0-06-084259-8.
  134. ↑ Kopelowicz A, Liberman RP, Zarate R (October 2006). "Recent advances in social skills training for schizophrenia". Schizophrenia Bulletin. 32 (Suppl 1): S12-23. doi:10.1093/schbul/sbl023. PMC   2632540 . PMID   16885207.
  135. ↑ Talwar N, Crawford MJ, Maratos A, Nur U, McDermott O, Procter S (November 2006). "Music therapy for in-patients with schizophrenia: exploratory randomised controlled trial". The British Journal of Psychiatry. 189 (5): 405–9. doi: 10.1192/bjp.bp.105.015073 . PMID   17077429.
  136. ↑ Ruddy R, Milnes D (October 2005). Ruddy R (ed.). "Art therapy for schizophrenia or schizophrenia-like illnesses". The Cochrane Database of Systematic Reviews (4): CD003728. doi:10.1002/14651858.CD003728.pub2. PMID   16235338.
  137. ↑ Ruddy RA, Dent-Brown K (January 2007). Ruddy R (ed.). "Drama therapy for schizophrenia or schizophrenia-like illnesses". The Cochrane Database of Systematic Reviews (1): CD005378. doi:10.1002/14651858.CD005378.pub2. PMID   17253555.
  138. ↑ Mosher LR (March 1999). "Soteria and other alternatives to acute psychiatric hospitalization: a personal and professional review". The Journal of Nervous and Mental Disease. 187 (3): 142–9. doi:10.1097/00005053-199903000-00003. PMID   10086470.
  139. ↑ Calton T, Ferriter M, Huband N, Spandler H (January 2008). "A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia". Schizophrenia Bulletin. 34 (1): 181–92. doi:10.1093/schbul/sbm047. PMC   2632384 . PMID   17573357.
  140. ↑ Bartholomeusz C (2011). Handbook of Schizophrenia Spectrum Disorders, Volume III: Therapeutic Approaches, Comorbidity, and Outcomes. Springer. p. 189. ISBN   9789400708341.
  141. ↑ Craig, Tom KJ; Rus-Calafell, Mar; Ward, Thomas; Leff, Julian P; Huckvale, Mark; Howarth, Elizabeth; Emsley, Richard; Garety, Philippa A (January 2018). "AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial". The Lancet Psychiatry. 5 (1): 31–40. doi:10.1016/s2215-0366(17)30427-3. ISSN   2215-0366. PMC   5746597 .
  142. ↑ "AVAtalk | AVATAR therapy made accessible" . Retrieved 2024-10-20.
  143. ↑ Aali G, Kariotis T, Shokraneh F (May 2020). "Avatar Therapy for people with schizophrenia or related disorders". The Cochrane Database of Systematic Reviews. 2020 (5): CD011898. doi:10.1002/14651858.CD011898.pub2. PMC   7387758 . PMID   32413166.
  144. ↑ Ng QX, Soh AY, Venkatanarayanan N, Ho CY, Lim DY, Yeo WS (2019). "A Systematic Review of the Effect of Probiotic Supplementation on Schizophrenia Symptoms". Neuropsychobiology. 78 (1): 1–6. doi: 10.1159/000498862 . PMID   30947230.
  145. ↑ Patrick RP, Ames BN (June 2015). "Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior". FASEB Journal. 29 (6): 2207–22. doi: 10.1096/fj.14-268342 . PMID   25713056. S2CID   2368912.
  146. ↑ Lim SY, Kim EJ, Kim A, Lee HJ, Choi HJ, Yang SJ (July 2016). "Nutritional Factors Affecting Mental Health". Clinical Nutrition Research. 5 (3): 143–52. doi:10.7762/cnr.2016.5.3.143. PMC   4967717 . PMID   27482518.
  147. ↑ Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L (November 2019). "Interventions for prodromal stage of psychosis". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD012236.pub2. PMC   6823626 . PMID   31689359.
  148. ↑ Elkis H, Buckley PF (June 2016). "Treatment-Resistant Schizophrenia". The Psychiatric Clinics of North America. 39 (2): 239–65. doi:10.1016/j.psc.2016.01.006. PMID   27216902.
  149. 1 2 3 4 5 Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH (13 January 2017). "Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review". BMC Psychiatry. 17 (1): 12. doi: 10.1186/s12888-016-1177-y . PMC   5237235 . PMID   28086761.
  150. ↑ Siskind D, Siskind V, Kisely S (November 2017). "Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis". Canadian Journal of Psychiatry. 62 (11): 772–777. doi:10.1177/0706743717718167. PMC   5697625 . PMID   28655284.
  151. ↑ van Os J, Kapur S (August 2009). "Schizophrenia" (PDF). Lancet. 374 (9690): 635–45. doi:10.1016/S0140-6736(09)60995-8. PMID   19700006. S2CID   208792724. Archived from the original (PDF) on 23 June 2013. Retrieved 23 December 2011.
  152. ↑ Picchioni MM, Murray RM (July 2007). "Schizophrenia". BMJ. 335 (7610): 91–5. doi:10.1136/bmj.39227.616447.BE. PMC   1914490 . PMID   17626963.
  153. ↑ Essali A, Al-Haj Haasan N, Li C, Rathbone J (January 2009). "Clozapine versus typical neuroleptic medication for schizophrenia". The Cochrane Database of Systematic Reviews. 2009 (1): CD000059. doi:10.1002/14651858.CD000059.pub2. PMC   7065592 . PMID   19160174.
  154. 1 2 3 4 5 Potkin SG, Kane JM, Correll CU, et al. (7 January 2020). "The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research". npj Schizophrenia. 6 (1): 1. doi:10.1038/s41537-019-0090-z. PMC   6946650 . PMID   31911624.
  155. ↑ Sinclair DJ, Zhao S, Qi F, et al. (19 March 2019). "Electroconvulsive therapy for treatment-resistant schizophrenia". The Cochrane Database of Systematic Reviews. 2019 (3): CD011847. doi:10.1002/14651858.CD011847.pub2. PMC   6424225 . PMID   30888709.
  156. 1 2 Miyamoto S, Jarskog LF, Fleischhacker WW (November 2014). "New therapeutic approaches for treatment-resistant schizophrenia: a look to the future". Journal of Psychiatric Research. 58: 1–6. doi:10.1016/j.jpsychires.2014.07.001. PMID   25070124.
  157. 1 2 Sriretnakumar V, Huang E, Müller DJ (2015). "Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update". Expert Opinion on Drug Metabolism & Toxicology. 11 (11): 1709–31. doi:10.1517/17425255.2015.1075003. PMID   26364648. S2CID   207492339.
  158. ↑ Agarwal P, Sarris CE, Herschman Y, Agarwal N, Mammis A (December 2016). "Schizophrenia and neurosurgery: A dark past with hope of a brighter future". Journal of Clinical Neuroscience. 34: 53–58. doi:10.1016/j.jocn.2016.08.009. PMID   27634495. S2CID   6929780.
  159. 1 2 Nucifora FC, Woznica E, Lee BJ, Cascella N, Sawa A (November 2019). "Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives". Neurobiology of Disease. 131: 104257. doi:10.1016/j.nbd.2018.08.016. PMC   6395548 . PMID   30170114.
  160. ↑ Servonnet A, Samaha AN (February 2020). "Antipsychotic-evoked dopamine supersensitivity". Neuropharmacology. 163: 107630. doi:10.1016/j.neuropharm.2019.05.007. PMID   31077727. S2CID   147704473.
  161. ↑ "Skitsofreniapotilaiden tuettu työllistyminen". www.kaypahoito.fi. Retrieved 2023-04-03.
  162. ↑ Richter, D.; Hoffmann, H. (September 2017). "Independent housing and support for people with severe mental illness: systematic review". Acta Psychiatrica Scandinavica. 136 (3): 269–279. doi:10.1111/acps.12765. ISSN   1600-0447. PMID   28620944. S2CID   32054475.
  163. ↑ McPherson, Peter; Krotofil, Joanna; Killaspy, Helen (2018-05-15). "Mental health supported accommodation services: a systematic review of mental health and psychosocial outcomes". BMC Psychiatry. 18 (1): 128. doi: 10.1186/s12888-018-1725-8 . ISSN   1471-244X. PMC   5952646 . PMID   29764420.
  164. ↑ Shen X, Xia J, Adams CE (October 2014). "Acupuncture for schizophrenia". The Cochrane Database of Systematic Reviews. 2014 (10): CD005475. doi:10.1002/14651858.CD005475.pub2. PMC   4193731 . PMID   25330045.
  165. ↑ van den Noort M, Yeo S, Lim S, Lee SH, Staudte H, Bosch P (March 2018). "Acupuncture as Add-On Treatment of the Positive, Negative, and Cognitive Symptoms of Patients with Schizophrenia: A Systematic Review". Medicines. 5 (2): 29. doi: 10.3390/medicines5020029 . PMC   6023351 . PMID   29601477.
  166. ↑ Deng H, Xu J (June 2017). "Wendan decoction (Traditional Chinese medicine) for schizophrenia". The Cochrane Database of Systematic Reviews. 2017 (6): CD012217. doi:10.1002/14651858.CD012217.pub2. PMC   6481906 . PMID   28657646.
  167. ↑ Wieland LS, Santesso N (October 2017). "Summary of a Cochrane review: Wendan decoction traditional Chinese medicine for schizophrenia". European Journal of Integrative Medicine. 15: 81–82. doi:10.1016/j.eujim.2017.09.009. PMC   5649251 . PMID   29062436.
  168. 1 2 3 Pinault D (March 2017). "A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway". Brain Sciences. 7 (4): 34. doi: 10.3390/brainsci7040034 . PMC   5406691 . PMID   28350371.
  169. 1 2 3 4 Nathou C, Etard O, Dollfus S (2019). "Auditory verbal hallucinations in schizophrenia: current perspectives in brain stimulation treatments". Neuropsychiatric Disease and Treatment. 15: 2105–2117. doi: 10.2147/NDT.S168801 . PMC   6662171 . PMID   31413576.
  170. ↑ Greenhalgh J, Knight C, Hind D, Beverley C, Walters S (March 2005). "Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies". Health Technology Assessment. 9 (9): 1–156, iii–iv. doi: 10.3310/hta9090 . PMID   15774232.
  171. ↑ National Institute for Health and Clinical Excellence (April 2003). "The clinical effectiveness and cost effectiveness of electroconvulsive Therapy (ECT) for depressive illness, schizophrenia, catatonia and mania". National Institute for Health and Clinical Excellence. Retrieved 2007-06-17.
  172. ↑ Mashour GA, Walker EE, Martuza RL (June 2005). "Psychosurgery: past, present, and future". Brain Research. Brain Research Reviews. 48 (3): 409–19. doi:10.1016/j.brainresrev.2004.09.002. PMID   15914249. S2CID   10303872.
  173. ↑ Laupu WK (2014). The efficacy of Garcinia mangostana L. (mangosteen) pericarp as an adjunctive to second-generation antipsychotics for the treatment of schizophrenia: a double blind, randomised, placebo-controlled trial (phd). James Cook University. 40097. Retrieved April 24, 2017.
  174. ↑ Helman DS (2018). "Recovery from schizophrenia: An autoethnography". Deviant Behavior. 39 (3): 380–399. doi:10.1080/01639625.2017.1286174. S2CID   151705012.
  175. ↑ Tyrer P (June 2019). "Nidotherapy: a cost-effective systematic environmental intervention". World Psychiatry. 18 (2): 144–145. doi:10.1002/wps.20622. PMC   6502418 . PMID   31059613.
  176. ↑ Ruddle A, Mason O, Wykes T (July 2011). "A review of hearing voices groups: evidence and mechanisms of change". Clin Psychol Rev. 31 (5): 757–66. doi:10.1016/j.cpr.2011.03.010. PMID   21510914.
  177. ↑ Corstens D, Longden E, McCarthy-Jones S, Waddingham R, Thomas N (July 2014). "Emerging perspectives from the hearing voices movement: implications for research and practice". Schizophr Bull. 40 (Suppl 4): S285–94. doi:10.1093/schbul/sbu007. PMC   4141309 . PMID   24936088.
  178. ↑ Chien WT, Clifton AV, Zhao S, Lui S, et al. (Cochrane Schizophrenia Group) (April 2019). "Peer support for people with schizophrenia or other serious mental illness". The Cochrane Database of Systematic Reviews. 4 (6): CD010880. doi:10.1002/14651858.CD010880.pub2. PMC   6448529 . PMID   30946482.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.